Cochlear

Cochlear EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Cochlear (COH.AX) as of Oct 4, 2026 is 36.84. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 27.67 — a change of 33.14% (higher).

EV/EBITDA

36.84

YoY

33.14%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Cochlear is 2026 36.84 . EV/EBITDA (Enterprise Value to EBITDA) of Cochlear was 2025 27.67 . It decreases by 33.14% higher compared to the previous year.

The Cochlear EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2019
31.84 AUD
Jan 1, 2020
42.67 AUD
Jan 1, 2021
32.50 AUD
Jan 1, 2022
29.63 AUD
Jan 1, 2023
28.04 AUD
Jan 1, 2024
21.11 AUD
Jan 1, 2025
27.67 AUD
Jan 1, 2026
36.84 AUD
The Cochlear EV/EBITDA history
YEAREV/EBITDAYoY
36.84+33.14%
27.67+31.10%
21.11-24.74%
28.04-5.36%
29.63-8.84%
32.50-23.82%
42.67+34.01%
31.84-3.27%
32.92-9.04%
36.19-16.72%
43.45-21.90%
55.63-25.84%
75.01—
Access this data via the Eulerpool API

Cochlear Stock analysis

What does Cochlear do? Cochlear Ltd is an Australian-based medical technology company founded in 1981 by engineer Professor Graeme Clark. The company specializes in Cochlear implant systems and other hearing devices. Cochlear Ltd offers accessories, services, and rehabilitation training for individuals with hearing impairments. The company's products are available for both children and adults with varying degrees of hearing loss. Cochlear Ltd operates in different sectors, including Cochlear implant systems, hearing aids, and wireless accessories and streaming systems under the brand names Nucleus® and Baha®. Nucleus® systems utilize a fully implantable cochlear implant and external speech processor to convert sound into electrical signals for interpretation by the brain. Baha® systems are bone-anchored hearing devices for individuals with unilateral to moderate hearing impairments. Cochlear Ltd also provides wireless accessories and streaming systems to connect devices like mobile phones, TVs, and music players to the hearing aids and cochlear implants, improving hearing performance and enhancing social lives. The company has a strong global presence, operating in over 100 countries with headquarters in Australia, multiple production facilities, and research centers. Cochlear Ltd has received numerous awards and recognition for its products and services and is committed to researching and developing new therapies and technologies to improve the lives of individuals with hearing impairments. Cochlear is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cochlear stock

EV/EBITDA (Enterprise Value to EBITDA) of Cochlear is 36.84 in 2026.

EV/EBITDA (Enterprise Value to EBITDA) of Cochlear changed from 27.67 to 36.84, representing a 33.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Cochlear since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Cochlear with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Cochlear

All Key Metrics — Cochlear